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Abstract
Background: Impaired proliferation of hepatocytes has been reported in chronic Hepatitis C virus
infection. Considering the fundamental role played by cell cycle proteins in controlling cell
proliferation, altered regulation of these proteins could significantly contribute to HCV disease
progression and subsequent hepatocellular carcinoma (HCC). This study aimed to identify the
alterations in cell cycle genes expression with respect to early and advanced disease of chronic
HCV infection.
Methods: Using freshly frozen liver biopsies, mRNA levels of 84 cell cycle genes in pooled RNA
samples from patients with early or advanced fibrosis of chronic HCV infection were studied. To
associate mRNA levels with respective protein levels, four genes (p27, p15, KNTC1 and MAD2L1)
with significant changes in mRNA levels (> 2-fold, p-value < 0.05) were selected, and their protein
expressions were examined in the liver biopsies of 38 chronic hepatitis C patients.
Results: In the early fibrosis group, increased mRNA levels of cell proliferation genes as well as
cell cycle inhibitor genes were observed. In the advanced fibrosis group, DNA damage response
genes were up-regulated while those associated with chromosomal stability were down-regulated.
Increased expression of CDK inhibitor protein p27 was consistent with its mRNA level detected
in early group while the same was found to be negatively associated with liver fibrosis. CDK
inhibitor protein p15 was highly expressed in both early and advanced group, but showed no
correlation with fibrosis. Among the mitotic checkpoint regulators, expression of KNTC1 was
significantly reduced in advanced group while MAD2L1 showed a non-significant decrease.
Conclusion: Collectively these results are suggestive of a disrupted cell cycle regulation in HCV-
infected liver. The information presented here highlights the potential of identified proteins as
predictive factors to identify patients with high risk of cell transformation and HCC development.
Background
Infection with HCV accounts for a vast majority of viral
hepatitis cases. A recent report suggests its prevalence in
geographically diverse areas, affecting around 130 million
people worldwide [1]. In Pakistan, the frequency of HCV
infection is estimated to be around 6% in general popula-
tion [2]. These figures are alarming, as patients currently
asymptomatic with relatively mild disease may eventually
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progress to complications of chronic liver disease like, cir-
rhosis, end-stage liver disease and hepatocellular carci-
noma (HCC). According to a recent review published by
Raza et al., 45% cases of HCC in Pakistan were found to
be positive for HCV antibody [3]. Epidemiological and
clinical studies have also demonstrated a causative role of
HCV infection in the development of HCC [4], albeit the
underlying mechanism is not fully known.
Liver injury is generally believed to be initiated by the
death of infected cells afflicting problems of inflamma-
tion, regenerative hepatocyte proliferation and fibrosis in
the surroundings [5]. In chronic HCV infection, rounds of
hepatic cell destruction and regeneration along with fibro-
sis occur as a result of persistent inflammation. This phe-
nomenon provides the pathogenic basis of HCV
associated liver disease. Together, these events keep the
dividing hepatocytes susceptible to cellular insult and
hence putting them at a greater risk of acquiring muta-
tions.
The molecular events during proliferation are tightly con-
trolled by the cell cycle regulators. During the cell cycle,
flawless DNA replication and chromosome segregation
are achieved by means of quality control checkpoints that
are active at each of the four phases of cell cycle namely
Gap1 (G1), DNA synthesis (S), Gap2 (G2) and Mitosis
(M). Progression through the phases of cell cycle is driven
by temporal activation of specific protein kinase com-
plexes consisting of cyclins and cyclin dependent kinases
(CDKs) [6]. In response to cellular insults, such as DNA
damage and oxidative stress, inhibitory checkpoint regu-
lators are activated at G1, S and G2 phases and stall the
progression of cell cycle [7]. These regulators include DNA
damage response genes (RAD1, HUS1, RAD9, ATM, ATR
and p53) [8] and members of CDK inhibitor family, p16
(CDKN2A), p15 (CDKN2B), p21 (CDKN1A) and p27
(CDKN1B) [9]. In the subsequent M phase, mitotic check-
point proteins of MAD and BUB families are responsible
for a proper chromosomal segregation during cell division
[10].
Studies performed on hepatic biopsies from chronic hep-
atitis C patients have shown an imbalance at G1/S check-
point of cell cycle [11,12]. In fact, the report from Marshal
et al showed a G1 arrest in hepatocytes characterized by
over expression of CDK inhibitor p21. In our previous
work [13] this arrest was further described by showing
altered expression of tumor suppressor p53 and apoptotic
proteins Caspase-3 and Bcl-2. Although these reports sug-
gest modulations of cell cycle events in hepatocytes dur-
ing the course of HCV-mediated disease progression, a
detailed analysis of cell cycle regulators involved at other
checkpoints still needs to be performed.
In order to determine the contribution of cell cycle genes
in HCV-induced disease progression, we have studied the
altered expression of cell cycle genes in HCV infected liver
biopsy tissues. This might be considered as an initial step
towards the prevention of chronic HCV disease progres-
sion into HCC. The mRNA expression of eighty four cell
cycle genes were first examined in pooled RNA samples
from patients with early or advanced HCV disease, and in
normal liver RNA of an uninfected individual. This analy-
sis identifies a list of differentially expressed genes
involved at cell cycle checkpoints. The translational levels
of four differentially expressed genes (p15, p27, KNTC1
and MAD2L1) were further examined. These genes were
selected on the basis of their crucial roles at G1/S and
mitotic checkpoints, in 38 chronic HCV infected tissues
using immunohistochemistry or western blotting. The
results showed significant association of p27 and KNTC1
with the progression of liver fibrosis.
Methods
Tissue Samples
After obtaining approval from the ethical review commit-
tee at the Aga Khan University, and informed consent
from the patients, liver biopsy specimens were collected
from thirty eight untreated chronic hepatitis C patients
and six non-viral hepatitis patients. Each sample was
apportioned into two pieces; one was frozen at -80°C and
other was fixed in formalin. An experienced liver patholo-
gist performed the histopathological grading and staging
on formalin-fixed paraffin embedded tissue samples,
employing Batts and Ludwig scoring system [14]. Fibrosis
stage was F0, F1, F2, F3 and F4 in 5, 9, 6, 10 and 8 patients,
respectively. Paraffin embedded tissues from individuals
who had normal liver histology (n = 4) as determined by
light microscopy, were also included as controls in the
immunohistochemistry experiments.
Sample Preparation and Quantitative RT-PCR
For transcriptional studies eight liver specimens were
selected; four with F0-1, designated as early HCV disease
and four with F3-4, designated as advanced HCV disease
(Table 1a). Total RNA from frozen liver tissues was
extracted in TRIzol reagent (Invitrogen, MD, USA). The
extract was made DNA free by digestion with RNase-free
DNase (Invitrogen, MD, USA) using 0.2 U/1 μg RNA and
incubation at 37°C for 10 to 30 minutes followed by
DNase inactivation at 75°C for 5 minutes. For PCR array
experiments, human cell cycle RT2 profiler PCR array
(SuperArray Bioscience, MD) was used to simultaneously
examine the mRNA levels of 89 cell cycle genes (list of
genes is available at http://www.superarray.com), includ-
ing five "housekeeping genes" in pooled RNA samples
from early and advanced HCV group. The pooled samples
were prepared by mixing equal amounts of liver tissue
RNA from four patients of each group. Previous studies
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have described RNA pooling as an appropriate initial
screening approach [15]. Given the limited availability of
liver biopsies from normal liver patients, total RNA of
normal, non-diseased liver purchased from Ambion (Palo
Alto, CA) was used as a reference standard in these exper-
iments. Reverse transcription was performed at 37°C for
1 hour with ReactionReady first strand cDNA Synthesis
Kit (SuperArray Biosciences, MD) using 1 μg of total RNA.
The synthesized cDNA was subjected to PCR amplifica-
tion using RT2 profiler PCR arrays according to manufac-
turers' instructions. The PCR conditions used were as
follows; 95°C for 10 minutes followed by 40 cycles at
95°C for 30 seconds and 60°C for one minute. Each
experiment was performed in duplicate or triplicate on
iCycler iQ Real Time PCR system (BioRad Laboratories).
Of the 5 housekeeping genes, GAPDH was used for nor-
malization. Fold change in expression of different groups
was calculated using ΔΔCt method [16]. A p-value of ≤
0.05 and a fold change of ≥ 2 in gene expression was taken
as significant.
Antibodies
The following antibodies were used for immunohisto-
chemistry at the dilutions given in parentheses; Mouse
monoclonal antibodies to p27 (DCS-72.F6, 1:50) and
p15 (15P06, 1:25) were purchased from Abcam (Cam-
bridge, UK). For western blotting monoclonal antibodies
against MAD2L1 (17D10, 1:500) and KNTC1 (10H4,
1:1000) were purchased from Abcam (Cambridge, UK)
and AbNova (Taiwan), respectively.
Immunohistochemistry
For immunohistochemistry 4-micron thin sections of par-
affin-embedded liver tissues (Table 1b) were deparaffin-
ized and rehydrated using a xylene-alcohol sequential
wash. The sections were then subjected to antigen retrieval
by heating in 0.01 M citrate buffer (pH 6.0) using a pres-
sure-cooker. EnVision Kit (Dako, Hamburg, Germany)
was used for immunostaining essentially following the
manufacturer's protocol. Briefly, endogenous peroxidase
was blocked for 5 min in 0.03% H2O2. Sections washed in
Tris-buffered saline with Tween 20 (TBST; 0.05 mol/l Tris
and 0.15 mol/l NaCl, pH 7.6, 0.1% Tween20) were incu-
bated with primary antibodies for 1 hour at room temper-
ature. Thereafter, a horseradish peroxidase (HRP)-labelled
polymer conjugated with a secondary antibody was
applied. The staining was visualized with 3, 3'-diami-
nobenzidine tetrahydrochloride (DAB). Finally, the slides
were counterstained with haematoxylin and mounted in
DPEX for examination. The immunostained sections were
examined using Nikon Eclipse E8000 and image analysis
system, (Nikon, Japan). Quantification of positive hepa-
tocytes was undertaken by two independent observers
counting approximately 1000 hepatocytes at magnifica-
tion 400× in five randomly selected fields. The positive
hepatocytes were expressed as a percentage of the total
cells counted in each case and values for subsequent anal-
ysis were obtained from the mean of the two independent
observations.
Protein Extraction and Western Blotting
Proteins were isolated from the organic phase of TRIzol
extraction as described in manufacturer's protocol. Iso-
lated proteins were heat denatured in electrophoresis
sample buffer (62 mM Tris-Cl, pH 6.8, 0.2% glycerol, 2%
SDS, 0.04% β-mercaptoethanol, 0.04% bromophenol
blue) and loaded onto 12% SDS-polyacrylamide gel. After
electrophoresis on the gel, separated protein bands were
transferred onto a PVDF membrane (Amersham, Ger-
many). Membranes were blocked with 5% Blotting Grade
Table 1: Demographic features of the study patients
Mean Age (years) Gender (male/female) Virus infection *Stage of Fibrosis *Grade of 
Inflammation
a) Patients included in PCR array experiments
Early HCV
(n = 4)
40 ± 6.2 2/2 HCV 0–1 0–1
Advanced
HCV
(n = 4)
53 ± 4.9 2/2 HCV 3–4 3–4
b) Patients included in Immunohistochemistry experiments
Chronic HCV
(n = 38)
42+9.3 18/20 HCV 0–4 1–4
Non-viral hepatitis (n = 6) 49 ± 2.1 2/4 None 1–4 1–3
Normal
(n = 4)
26 ± 4.0 2/2 None - -
* Histopathological staging and grading of tissue samples were performed according to Batts Ludwig scoring system.
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Blocker non-fat dry milk powder overnight at 4°C. The
membrane was incubated with primary antibody diluted
in 1× TBST (Tris-buffered saline, 0.1% Tween 20) on an
orbital shaker, followed by three washings in TBST for 10
mins. After washing, the membrane was incubated with
horse radish peroxidase-labelled anti-mouse IgG
(1:10,000) for 1 h on an orbital shaker at room tempera-
ture. Membrane was washed with 1× TBST three times for
10 min on a shaker. The blot was developed with ECL Plus
reagent (Amersham, Germany) according to manufac-
turer's instructions. Actin was included as internal loading
control and detected by Anti-actin (Santa Cruz). Band
intensities were measured using Image J software (NIH,
USA).
Statistical Analysis
Significant fold change in mRNA levels of each gene
between the groups was tested using t-test as indicated by
the manufacturer (SuperArray, MD). Analyses of immu-
nostaining data were performed using the Statistical Pack-
age for Social Sciences (SPSS, 14.0). Association between
the expression of p27, p15, KNTC1 and MAD2L1with his-
tological feature fibrosis was analyzed using Johnkhere
Terpestra test or Mann Whitney U-test. Correlations
among the groups were evaluated by Spearman's rank cor-
relation coefficient. A p-value of less than 0.05 was con-
sidered significant.
Results
Transcriptional Profile of Cell Cycle Pathway Genes
In order to assess the extent of modulation in cell cycle
gene expression during chronic infection, PCR arrays of
84 cell cycle genes were performed in RNA samples sepa-
rately pooled from early HCV, advanced HCV and com-
mercial preparation of human normal liver RNA. The
mean GAPDH threshold cycle (Ct) values for early HCV,
advanced HCV and normal liver were 22.45 ± 0.5, 22.95
± 0.42 and 22.0 ± 0.21 respectively. Comparisons of
mRNA expressions of cell cycle genes, made between, 1)
normal liver to early HCV and 2) early HCV to advanced
HCV, revealed that fifteen (18%) of the 84 cell cycle genes
were not detectable in any of the comparative groups,
when Ct value greater than 35 was applied as a cutoff for
significant expression.
The mRNA expression of 22 (31%) of the remaining 69
genes showed more than 2-fold change in early HCV ver-
sus normal liver (Table 2). Seven (32%) of these showed
significant increase which include proliferation genes
Mcm-2 and cyclin E1, DNA repair gene GADD45α
(Growth arrest and DNA damage 45α), CDK inhibitor
CDKN1B/p27 and G2-M phase regulatory genes KNTC1,
DNM2 and CDC16 (see additional file 1).
In early versus advanced HCV comparison, 23 (33%) of
the 69 genes showed more than 2-fold change (Table 3).
Nine (29%) of these genes were significantly differentially
expressed which include DNA damage response genes
RPA3, RAD1, HUS1 and CDK inhibitors CDKN2B/p15,
CDKN3 that were found up-regulated whereas tumor sup-
pressor protein p53 and mitotic checkpoint protein
MAD2L1 were found down regulated (see additional file
1).
Protein Expression of CDK Inhibitors
Experiments performed to evaluate the differential expres-
sion of cell cycle genes showed significant change in the
expression of CDK inhibitors p27 and p15. Further inves-
tigation focusing on the expression of their corresponding
proteins in paraffin embedded sections from 38 chronic
hepatitis C patients (14 cases with F0 or F1, 6 cases with
F2 and 18 cases with F3 or F4) resulted in varied profile.
The p27 protein was found up-regulated in normal to
early HCV while the p15 levels appeared to remain unal-
tered in early to advanced HCV. The immunostaining of
each protein was localized in the nucleus of hepatocytes
(Figure 1 &2) with few cases showing positivity in portal
vein area as well. Expression of p27 was detected in the
liver of 30/38 (78.9%) patients with chronic HCV infec-
tion. The percentage of p27 positive hepatocytes in early
HCV (median = 22.6%, range = 4.3 – 37.4) was signifi-
cantly higher as compared to normal liver (median = 4%,
range = 1.3 – 6.3) (Mann-Whitney U test, p = 0.001)
which was similar to the observations at transcriptional
level. In advanced HCV the median and range of p27
expression were 17.3% and 3.0 – 32.0, respectively. The
association of p27 expression with HCV-related F0 to F4
showed a significant decrease in p27 expression with the
progression of fibrosis (Johnkhere Terpestra Test, p = 0.04,
Figure 3). In non-viral hepatitis, p27 expression was rarely
detected (see additional file 2).
Immunostaining of p15 was not evident in normal liver
and non-viral hepatitis except in 1 case see additional file
2). p15 expression was nonetheless observed in 27/38
(71%) chronic HCV infected liver tissues. In contrast to
what was observed at mRNA level a non-significant
decrease in p15 expression was observed in early to
advanced HCV comparison (median = 25%, range = 0–39
versus 21%, range = 13–37). Likewise, no significant asso-
ciation was found with the progression of fibrosis.
Protein Expression of Mitotic Checkpoint Regulators
Two of the mitotic checkpoint proteins KNTC1 and
MAD2L1 showed significant alterations in cell cycle array
experiments. Owing to the limited amount of total pro-
teins available from fresh frozen liver biopsies, the protein
levels of both of these mitotic regulators were analyzed in
25 out of 38 chronic HCV patients and 4 non-viral hepa-
BMC Infectious Diseases 2009, 9:125 http://www.biomedcentral.com/1471-2334/9/125
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Table 2: List of differentially expressed cell cycle genes >2 fold in early HCV relative to normal liver.
Gene Symbol Average Ct Early HCV Average Ct Normal T-test
p-value
Fold change
Cell cycle progression/cell proliferation genes
MCM2 30.85 33.4 0.05 7.670
CDC2 32.5 34.15 0.36 4.79
MCM5 28.15 29.5 0.16 3.390
MCM3 28.0 29.1 0.11 3.100
CCNE1 33.6 34.9 0.05 4.76
CDK Inhibitors
CDKN1A 27.5 28.2 0.258 2.24
CDKN1B 27.65 28.6 0.034 2.36
G2/M checkpoint gene
GADD45A 27.15 29.8 0.03 9.000
DNM2 31.75 29.6 0.005 -2.65
KPNA2 31.3 29.25 0.169 -3.730
Mitotic checkpoint genes
KNTC1 31.6 34.4 0.04 9.19
CKS1B 31.0 33.5 0.17 7.200
MAD2L1 32 34.55 0.077 7.07
CDC34 30.0 31.3 0.35 3.4
CDC16 32.6 30.8 0.027 -2.16
DNA damage response genes
CHEK1 32.35 33.70 0.24 3.09
HUS1 29.65 27.05 0.06 -4.37
Cell cycle Regulators
HERC5 29.3 33.7 0.07 20.393
CCNG2 29.85 32.3 0.11 6.400
RBBP8 31.7 30 0.108 -2.300
BCL2 29.65 31.60 0.052 3.10
UBE1 29.55 27.4 0.206 -3.500
The values present average Ct values without normalization and fold differences observed in Real time PCR and p-values of T-test (values ≤ 0.05 are 
in bold).
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Table 3: List of differentially expressed cell cycle genes >2 fold in advanced HCV relative to early HCV
Gene symbol Average Ct Adv. HCV Average Ct Early HCV T-test
p-value
Fold change
Cell proliferation genes
CCND1 32.65 31.00 0.14 -2.22
CCND2 31.3 32.35 0.05 5.00
CDK2 32.1 30.3 0.6 -2.46
CDK inhibitors
CDKN2B 32.4 33.50 0.04 3.03
CDKN3 34.20 32.73 0.05 5.46
CDKN1B 29.4 27.7 0.5 -2.3
G2/M checkpoint gene
KPNA2 30.85 31.3 0.98 2.75
HERC5 33.05 29.3 0.217 -8.70
DNA damage response genes
ATR 31.9 35 0.30 10.50
RAD1 30.4 32.8 0.05 6.46
HUS1 27.55 29.65 0.05 6.06
RAD17 28.45 30.35 0.057 5.27
RPA3 33.3 35.0 0.01 4.6
*TP53 30.80 27.03 0.04 -2.79
Mitotic checkpoint regulators
MAD2L1 35 32 0.04 -5.6
CDC34 32.65 30.00 0.025 -4.4
Cell cycle regulation
CCNH 32.85 35.0 0.5 5.00
CDK8 28.7 30.5 0.07 4.92
CCNG2 27.8 29.85 0.09 5.86
CKS2 30.7 32.15 0.23 3.86
CUL1 30.6 28.3 0.65 -3.48
TFDP2 28.2 30 0.08 4.92
CCNT1 28.6 31.15 0.08 4.59
The values present average Ct values without normalization and fold differences observed in Real time PCR and p-values of T-test (values ≤ 0.05 are 
in bold).
BMC Infectious Diseases 2009, 9:125 http://www.biomedcentral.com/1471-2334/9/125
Page 7 of 13
(page number not for citation purposes)
Expression of CDK inhibitor p27Figure 1
Expression of CDK inhibitor p27. Immunohistochemistry of p27 in normal liver and chronic HCV-infected liver with Early 
and Advanced HCV. Nuclear expression of the protein was observed in hepatocytes. Positive hepatocytes are stained brown 
(Mayer hematoxylin, magnification 400×).
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Expression of CDK inhibitor p15Figure 2
Expression of CDK inhibitor p15. Immunohistochemistry of p15 in normal liver and chronic HCV-infected liver with Early 
and Advanced HCV. Nuclear expression of the protein was observed in hepatocytes. Positive hepatocytes are stained brown 
(Mayer hematoxylin, magnification 400×).
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titis patients. Western blot analysis of KNTC1 detected its
band in 20/25 chronic HCV patients and in 2/4 non-viral
hepatitis patients (Figure 4a). A significant reduction (>2
fold, p < 0.01) in total KNTC1 levels was observed in
advanced HCV as compared to early HCV (Figure 4b). The
band of MAD2L1 was also detectable in 17/25 patients
while in non-viral hepatitis it was not detectable (Figure
4c). Consistent with the observations at mRNA levels a
slight decrease in its expression in advanced HCV group
was observed but that was not found statistically signifi-
cant (Figure 4d).
Discussion
In the present study, an unbiased PCR array approach
containing 84 cell cycle genes was applied on pooled RNA
samples, to identify altered gene expression in HCV-asso-
ciated liver disease. This analysis led to the identification
of differentially expressed genes involved at cell cycle
checkpoints, which may play a role in disease pathogene-
sis. Further investigation at protein level of four differen-
tially expressed genes, selected on the basis of their crucial
role in cell cycle regulation confirms the modulations in
the expression of CDK inhibitor p27 and mitotic check-
point genes MAD2L1 and KNTC1. It is important to note
that these cell cycle proteins have not been implicated pre-
viously in chronic liver disease. Moreover, the association
Negative Association of p27 with fibrosisFigure 3
Negative Association of p27 with fibrosis. Box-plot graphic display of p27 expression in hepatocytes of chronic HCV 
patients grouped according to fibrosis stage. The horizontal bar in middle of the box represents the median, the box stretches 
between the 25th and 75th percentile, and the upper and lower lines extend to the range of the data. (Jonckeere-Terpstra test p 
= 0.04).
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of p27 and KNTC1 expression with liver fibrosis suggests
a role of these markers in the progression of liver disease.
Persistent inflammation and cell destruction during HCV
infection has been suggested to induce proliferation of
normally quiescent hepatocytes [17-19], which helps in
restoring liver mass and maintaining hepatic function.
Moreover, previous reports including our own have
shown an arrested cell cycle in hepatocytes, during HCV
infection [12,13]. Consistent with these data we found
more than 3 fold increase in the mRNA levels of prolifer-
ation related genes Mcm-2, -3, -5, CDC2 and cyclin in
early HCV group while the mRNA levels of cell cycle
inhibitors p27, GADD45A, MAD2L1 and KNTC1 were
also found to be significantly increased (Table 2). These
transcriptional changes suggest a mixed population of
cells in the infected livers of chronic hepatitis C some of
which are in proliferating state while others in an arrested
state. In advanced HCV, cell cycle inhibitors p27 and
MAD2L1 were found down-regulated while p15/
CDKN2B and CDKN3 were up-regulated. More than four
fold increase was also observed in the mRNA levels of
DNA damage response genes ATR, HUS1, RAD1, RPA3
and RAD17 (Table 3) suggesting increased DNA damage.
These alterations were also accompanied by the down-reg-
ulation of tumor suppressor p53. Taken together these
results are suggestive of deregulated cell cycle in chronic
HCV infection that is considered as a consistent event in
HCC [20,21].
Reduced expression of mitotic checkpoint genes in chronic HCV patientsFig r  4
Reduced expression of mitotic checkpoint genes in chronic HCV patients. a & c) Western blotting for MAD2L1 and 
KNTC1 was done in total protein extracts prepared from biopsy specimens of chronic hepatitis C or Non-viral hepatitis 
patients (NVH). Following SDS-PAGE (12% gel) and transfer, the nitrocellulose membranes were probed with monoclonal 
antibodies to MAD2L1, which recognizes both phosphorylated and de-phosphorylated forms and KNTC1. b & d) Densitome-
try analysis of total MAD2L1 or KNTC1 expression normalized to their respective loading controls (β-actin) was done using 
Image J software. The number of samples analyzed in each group (n) is indicated below each column. The p-values at the top of 
the column compare early HCV to advanced HCV. Represented are mean ± S.D.
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Association of CDK inhibitor p21 with impaired liver
regeneration and progressive liver fibrosis has been
reported earlier [22]. In the current study, analysis at pro-
tein level by immunohistochemistry in HCV-infected
hepatic biopsies showed a significant increase in the
expression of p27 protein (Figure 1) that belongs to the
same KIP family as p21. This protein is involved in inhib-
iting cell cycle progression at both G1 and S phases and is
also defined as a tumor suppressor protein [23]. Interest-
ingly, an inverse relationship between p27 protein expres-
sion and progression of liver fibrosis from F0 to F4 was
found (Figure 3). It would be pertinent to mention here
that mouse models of chronic injury induced-liver tumor-
genesis have shown that loss of p27 in advanced stages of
disease promotes tumor cell proliferation [24]. These
observations signify the potential of p27 as a marker for
prognostic implications in chronic HCV disease.
In contrast to p27, immunohistochemical evaluation of
G1 phase inhibitor p15 revealed no significant difference
in advanced HCV as compared to early HCV that conflicts
with the changes observed at mRNA level. This inconsist-
ency might have been due to decreased stability of p15
protein in advanced disease stages that increased the tran-
scription through a regulatory feedback mechanism to
maintain its levels. Another explanation for this inconsist-
ency could be the use of pooled samples of whole liver
lysates for mRNA expression while immunohistochemis-
try was done on individual formalin fixed paraffin embed-
ded biopsies. Together, the expression of p27 and p15 in
non-dividing hepatocytes might represent the population
of cells which are arrested in cell cycle and not participat-
ing much in liver compensation, but are more active met-
abolically.
Defects in chromosomal segregation are a common fea-
ture of liver tumor cells suggesting a possible role of mito-
sis deregulation in the pathogenesis of HCC [25]. While
examining the alterations of cell cycle genes in early and
advanced HCV, we found altered expression of mitotic
checkpoint genes, MAD2L1, KNTC1, CDC16 and CDC34.
KNTC1, also known as "rough deal protein" (ROD) is part
of a complex involved in elaborating an inhibitory signal
due to improper chromosomal alignment during cell divi-
sion [26], while member of Mad2 family, MAD2L1, par-
ticipates in inhibiting Anaphase promoting complex
(APC) [27] from ubiquitinating securin, whose degrada-
tion is a prerequisite for sister chromatid separation and
mitosis. Considering the crucial roles of KNTC1 and
MAD2L1 in chromosomal segregation, we analyzed their
respective proteins by western blotting. Results showed
increased levels of both of these proteins in early HCV that
is suggestive of mitotic checkpoint activation or mitotic
arrest in the liver cells. This is consistent with the down-
regulation of CDC16, which is a component of APC and
promote chromosomal segregation. Importantly, KNTC1
expression significantly decreases in advanced stages of
HCV group as compared to early HCV while the expres-
sion of MAD2L1 showed a modest reduction in advanced
HCV group (Figure 4). However, a possibility of error in
assessing these changes could come about due to the fact
that the expression of reference gene, β-actin also
increases with the progression of liver fibrosis.
The role of KNTC1 in human cancers is not well docu-
mented, however, a single report describes mutation in
this gene in colorectal carcinoma [28]. On the other hand,
depletion or reduced expression of MAD2 gene has been
reported in mammalian cells with loss of mitotic check-
point and subsequent chromosomal instability [29,30].
Thus, low expression of these mitotic checkpoint regula-
tors in advanced HCV might reflect loss of mitotic check-
point control that could render cells to chromosomal
instability. This hypothesis is also supported by a previous
study which showed presence of near-aneuploidy DNA
content in liver specimens from chronic hepatitis C
patients [11].
The altered expression of cell cycle regulators observed in
present study might be specific to hepatitis C as it was
rarely observed in non-viral hepatitis patients. Neverthe-
less, the low number of control liver samples, hold back
in achieving statistically significant differences between
the two groups, with varying degrees of fibrosis.
Conclusion
The analysis of cell cycle regulators showed altered expres-
sion of G1/S and M phase inhibitors in chronic HCV
infection which either arrest or delays the progression
through G1 and S phase as well as M phase, latter being
not reported earlier in chronic hepatitis C patients. These
cell cycle perturbations might be a consequence of
increased DNA damage or persistent inflammation during
viral infection that in turn could increase genetic instabil-
ity and cell transformation. The information presented
here laid down the basis for future studies to evaluate the
activation of the identified cell cycle genes in chronic hep-
atitis C patients as well as HCC patients infected with
HCV. These studies would be helpful to identify patients
with high risk of cell transformation and HCC develop-
ment.
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